EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions

Takashi Ishikawa, Emi Kurimoto, Adam A Joyal, Tatsuki Koike, Haruhide Kimura, Thomas E Scammell

Current Biology · 2025-05 · 35 (9) · 2088-2099.e4

DOI: 10.1016/j.cub.2025.03.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Biology, 2025-05. Verfasst von Takashi Ishikawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; …. Hauptthemen laut MEDLINE: Wakefulness, Orexins, Orexin Receptors, Cataplexy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A., Takeda Pharmaceutical Company Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narcolepsy type 1, caused by selective loss of the orexin-producing neurons, is characterized by poor maintenance of wakefulness and cataplexy. Clinical trials show that orexin receptor 2 (OX2R) agonists substantially improve narcolepsy symptoms, but the key brain regions through which OX2R signaling produces these benefits are only partially understood. To address this question, we produced recombinant mice expressing the human diphtheria toxin receptor driven by the endogenous orexin promoter (orexinDTR mice). After injection with diphtheria toxin, orexinDTR mice had severe and selective loss of the orexin neurons, leading to narcolepsy symptoms, including poor maintenance of wakefulness and cataplexy; these symptoms were substantially improved by an OX2R-selective agonist OX-201. We then crossed orexinDTR mice with OX2R transcription-disrupted (TD) mice to produce a new model lacking orexin neurons and OX2R. We focally restored OX2R expression in specific brain regions of OX2R TD::orexinDTR mice and assessed whether OX-201 improves specific aspects of narcolepsy. In mice expressing OX2R only in the tuberomammillary nucleus (TMN) or basal forebrain (BF) regions, OX-201 improved maintenance of wakefulness but did not suppress cataplexy. In contrast, in mice expressing OX2R in the ventrolateral periaqueductal gray and lateral pontine tegmentum (vlPAG/LPT), OX-201 suppressed cataplexy without improving maintenance of wakefulness. These results suggest that OX2R signaling in the TMN and BF regions can stabilize wakefulness and OX2R signaling in the vlPAG/LPT region can suppress cataplexy, providing key insights into how orexins regulate wakefulness and muscle tone and how OX2R agonists improve the symptoms of narcolepsy. VIDEO ABSTRACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WakefulnessOrexinsOrexin ReceptorsCataplexyBrainNarcolepsyAnimalsMiceMaleMice, TransgenicNeuronsMice, Inbred C57BLHumans

Stichwörter der Autor:innen

agonistcataplexyhypocretinnarcolepsyorexinorexin receptor 2sleepiness

Substanzen

OrexinsOrexin Receptors

Autor:innen und Institutionen

  • Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; Department of Neurology, Beth Israel Deaconess Medical Center and Harv…
  • Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
  • Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
  • Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. Electronic address: tscammel@bidmc.harvard.edu.

Förderung

  • Takeda Pharmaceuticals U.S.A.
  • Takeda Pharmaceutical Company Limited

Zitieren

APA

Ishikawa, T., Kurimoto, E., Joyal, A. A., Koike, T., Kimura, H., & Scammell, T. E. (2025). An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions. Current Biology, 35(9), 2088-2099.e4. https://doi.org/10.1016/j.cub.2025.03.040

Vancouver

Ishikawa T, Kurimoto E, Joyal AA, Koike T, Kimura H, Scammell TE. An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions. Current Biology. 2025;35(9):2088-2099.e4. doi:10.1016/j.cub.2025.03.040

BibTeX
@article{Ishikawa2025,
  author = {Ishikawa, Takashi and Kurimoto, Emi and Joyal, Adam A and Koike, Tatsuki and Kimura, Haruhide and Scammell, Thomas E},
  title = {An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions},
  journal = {Current Biology},
  year = {2025},
  volume = {35},
  number = {9},
  pages = {2088--2099.e4},
  doi = {10.1016/j.cub.2025.03.040}
}
Kostenlos starten →